Desmoid tumors are rare, benign, sometimes aggressive tumors resulting from unregulated proliferation of fibroblastlike cells (1, 2) . Their natural history is one of slow growth with progressive infiltration of surrounding soft tissues leading in some cases to strangulation of nerves and blood vessels. Abdominal desmoid tumors are the most common and can be classified into sporadic and familial forms (2) . In the latter case, inherited desmoid tumors are most frequently associated with familial adenomatous polyposis. At the molecular level, the development of desmoid tumors has been associated with a constitutive activation of the Wnt signaling pathway (3 -7) . Familial adenomatous polyposis -associated desmoid tumors are usually caused by germline adenomatous polyposis coli (APC) mutations followed by somatic inactivation of the wild-type APC allele (3 -5) , whereas sporadic desmoids are usually characterized by oncogenic mutations in the b-catenin gene, both identical molecular alterations to those found in the vast majority of colorectal cancers (3, 4) .
The management of patients is difficult and these tumors are prone to local recurrence. Surgery is an obvious option but the development of 10% to 30% of sporadic abdominal wall desmoid tumors and 68% to 86% of familial adenomatous polyposis -associated intra-abdominal tumors has been associated with surgical trauma (8) . As a result, there is currently no satisfactory treatment for these tumors, especially in the context of familial adenomatous polyposis -related desmoid tumors for which they represent a major cause of morbidity and mortality (1, 9) . Therefore, there is a need for alternative or complementary therapies that could delay surgery if not eradicate the tumor. In this context, gene therapy through direct injection of gene delivery vectors in the tumor mass has already been suggested through preclinical studies involving nonviral and replication-deficient adenoviral vectors (10, 11) .
Oncolytic adenoviruses are a class of adenoviruses genetically modified to selectively replicate in cancer cells (12, 13) . This selectivity can be achieved through deletions in the viral genome (14 -16) or replacement of the viral endogenous promoters by cancer-selective promoters (17 -19) . The resulting viruses have the unique property of tumor-dependent selfamplification. In addition, initial clinical trials have shown that these agents are very safe and well-tolerated (20) . Recently, adenoviruses with Tcf binding sites in the early promoters were generated and these oncolytic adenoviruses showed up to 100,000-fold selectivity for cells with activated Wnt signaling (17, 21) . As a constitutive activation of the Wnt signaling pathway is a common molecular defect in sporadic or familial desmoid tumors, the aim of the present study is to assess the efficacy of Wnt-selective oncolytic adenoviruses in these cells. In addition and as molecular imaging of gene transfer using the Na/I symporter (NIS) as a reporter gene could provide crucial information on the extent of gene transfer in vivo through positron emission tomography imaging (18, 22, 23) , we have generated a Wnt-selective oncolytic adenoviruses encoding hNIS. The efficacy of these viruses was assessed in vitro on primary tumor cells extracted from familial (n = 3) or sporadic (n = 3) desmoid tumors.
Materials and Methods
Establishment of primary cultures of desmoid cells, cell lines. Desmoid tumors samples were obtained following surgical resection. The protocol was used in conjunction with ethical approval from the Harrow or Leuven Research Ethics Committee. The tumors were macerated in small pieces with a scalpel and digested overnight at 37jC in RPMI containing 20% fetal bovine serum (AutogenBioclear, Ltd.), 100 units/mL penicillin, 100 Ag/mL streptomycin, and 0.2 Ag/mL Butyl-p-hydroxybenzoate supplemented with 1 mg/mL of Collagenase D (Roche Diagnostic GmbH). The digest was then filtered through a 100-Am nylon cell strainer and centrifuged twice at 1,000 rpm. Cell pellets were washed twice with PBS, resuspended in RPMI 20% fetal bovine serum containing antibiotics (see above), and seeded. Primary cultures were maintained in a 5% CO 2 atmosphere at 37jC. Erythrocytes and cell debris were washed away with PBS 24 h later. Germline and somatic mutations were identified as follows: Desmoid 1, SKBR3, MCF7, HPAF, SUIT-2 and DLD-1 cells were cultured as previously described (11, 24, 25) .
Generation and production of a Wnt-selective adenovirus encoding NIS. The plasmid vpKH1 encodes the genome of a Wnt-specific adenovirus in which TCF-4 binding sites are present in E1A, E1B, and E4 of the viral genome (21) . Insertion of the NIS cDNA in the gp19k of this adenovirus was done as previously described (18), using homologous recombination in yeast (26) . Virus were produced and titrated as previously described (27) .
Adenovirus nomenclature. AdWt, Wild-type adenovirus type 5. AdLacZ, Replication-deficient adenovirus type 5 encoding the b-galactosidase gene. Ad-hNIS, Replication-deficient adenovirus type 5 encoding the NIS coding sequence (23) . AdKH1, Adenovirus selectively replicating in cells in which the Wnt signaling pathway is constitutively activated (21) . AdIP2, Adenovirus selectively replicating in cells in which the Wnt signaling pathway is constitutively activated and encoding NIS.
Infections with adenoviruses. Cells were seeded at a cell density of 10 4 cells/cm 2 .
The following day, they were infected with adenoviruses at different multiplicity of infection (MOI) in serum-free medium for 30 to 45 min. Culture medium was then added to reach a serum concentration up to 20%.
Biochemical assays. Cell survival assays, measurement of green fluorescent protein -positive cells, and assessment of in vitro viral replication and E1A expression were done as previously described (18, 19, 28, 29) , respectively.
Coxsackievirus and adenovirus receptor staining. Cells for staining were collected by trypsinisation, and washed. The pellet was resuspended and incubated with the anti -coxsackievirus and adenovirus receptor (CAR) primary monoclonal mouse antibody (30) 1:500 in fluorescence-activated cell sorting (FACS) buffer containing 5% normal goat serum (Dako Cytonation) for 90 min on ice. Cells were then washed thrice and incubated for 30 min at room temperature in the dark with secondary antibody goat anti-mouse FITC 1:30 in FACS buffer. The cells were washed thrice, and the final pellet was resuspended in 400 AL FACS buffer. Measurement of the number of CAR-positive cells was done by FACS on at least 5 10 5 cells.
Results
Effect of Wnt-selective oncolytic adenoviruses on desmoid tumor cells. To determine whether the insertion of the NIS cDNA affects the selectivity of the Wnt-selective virus, DLD-1 colon cancer cells carrying an APC mutation that results in constitutively high h-catenin signaling (31) and cell lines in which the Wnt signaling pathway is not activated in normal culture conditions (MCF7, SKBR3) were infected with AdIP2 and a wild-type adenovirus type 5 as positive control. Table 1 shows that the EC 50 of AdIP2 and AdWt are in the same range in DLD-1 target cells, whereas AdWt is more than two log potent than AdIP2 on nontarget MCF7 or SKBR3 cells. These results show that AdIP2 can selectively kill cells in which the Wnt signaling pathway is constitutively activated.
To determine the effect of adenoviral infection on primary desmoid tumor cells, cells from sporadic (Fig. 1A) or familial adenomatous polyposis -related (Fig. 1B ) desmoid tumors were infected at different MOI with AdKH1 or AdIP2. Different levels of sensitivity to oncolytic adenoviral treatment were
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observed with the following range of sensitivity: desmoid 2 (sporadic) > desmoid 5 (familial); desmoid 5.2 (familial) > desmoid 3 (sporadic) > desmoid 1 (sporadic); desmoid 4 (familial). Statistical analysis showed a highly significant difference (P < 0.0001) between uninfected cells and cell infected with AdKH1 and AdIP2 at MOI 100 for desmoids 2, 3, 5, and 5.2. These results showed that the sensitivity to oncolytic adenoviral treatment is not related to the type of mutation in the Wnt signaling pathway or the sporadic or familial nature of desmoid tumors.
Correlation between infectivity and sensitivity to adenoviral vectors. The infectivity of primary cells extracted from the different desmoid tumors was determined by infection with a replication-deficient adenovirus (MOI, 10) encoding the green fluorescent protein and measurement of green fluorescent protein -positive cells by FACS. Figure 2 shows that the range of infectivity is similar to that obtained for the sensitivity to adenoviral infection (Fig. 1) . The CAR has been shown to act as a primary receptor to adenovirus and to play a critical role in viral entry in the cell (32) . Surprisingly, CAR staining was negative in all desmoid cell samples (data not shown). This is in sharp contrast to highly positive (>95%) A549 cells used as positive control (data not shown) and known to express high levels of CAR (33) . In an attempt to further show infection in the absence of CAR expression, E1A expression was monitored upon AdIP2 infection of Desmoid 3. Quantitative reverse transcription-PCR revealed that E1A expression was weak and hardly detectable 24 hours after infection but increased very significantly 4 days later (Supplementary Data), demonstrating that incubation of Desmoid 3 with AdIP2 lead to E1A expression resulting from cell infection, independently of the presence or CAR. Altogether, these results suggest that sensitivity to adenoviral agents and infectivity are tightly correlated and that a CAR-independent mechanism is involved in adenoviral infection of primary cells from desmoid tumors 2, 3, 5, and 5.2.
Replication of adenovectors in primary desmoid tumor cells sensitive to the viruses. To determine whether the reduced cell viability observed upon adenoviral infection of cells from desmoid 2, 3, 5, and 5.2 was associated with viral replication, DNA from cells infected with AdIP2 was collected 1 day or 4 days after infection. This DNA was subjected to quantitative PCR to titrate the amount of adenoviral DNA per culture well. Figure 3 shows that in all cases, viral amplification of the adenoviral genome was observed between day 1 and 4, suggesting replication of the oncolytic virus in these cells.
Additional toxic effect of the NIS transgene. In addition, at MOI 100, AdIP2, the NIS-positive virus is statistically more efficient (P < 0.0001 for the three tumors) than AdKH1 (NISnegative) in cells from desmoids 2, 5, and 5.2 ( Fig. 1) . To determine whether the presence of NIS in the viral genome and its expression is toxic for desmoid cells, independently from the oncolytic action of the virus, primary cells from the desmoid tumors 2, 5, and 5.2 were infected at a MOI of 100 with a replication-deficient recombinant adenovirus encoding either the h-galactosidase gene (Ad-LacZ) or NIS (Ad-hNIS) under the control of the immediate-early cytomegalovirus promoter. Figure 4 shows that the toxicity of Ad-hNIS is not observed with Ad-LacZ, suggesting a toxicity of the NIS gene product in desmoid tumor cells. By contrast, this hNIS cytotoxicity is not observed with established cell lines such as HPAF or SUIT-2 cells (Fig. 4) . 
Discussion
The Wnt signaling pathway is considered as the key molecular defect in sporadic or familial desmoid tumors (3 -5) , and therapeutic strategies targeting this pathway are expected to provide therapeutic benefits with minimal side effects in patients affected with this pathology. In this context, an oncolytic adenovirus, replicating selectively in cells in which the Wnt signaling pathway is constitutively activated is particularly relevant.
Replication-selective oncolytic adenoviruses represent a novel class of therapeutic agents. Preclinical and clinical studies have shown the safety and feasibility of the approach and their suitability for association with more classic cancer treatments such as chemotherapy has been shown (34 -36) . However, a clear limitation of adenoviral vectors is that only a minimal proportion of the injected dose reaches the tumors after systemic administration. As a result, intratumoral injections are advised. Considering the lack of metastasis and the size of the tumors observed in patients with desmoids (1), local injection of oncolytic adenovirus represents a practical approach that could even be implemented in conjunction with chemotherapy. Therefore, desmoid tumors are a relevant indication for adenoviral vectors.
Our data clearly show that primary cells from some desmoid tumors allow replication and are sensitive to the action of oncolytic adenoviruses. However, in two cases, the cells were completely refractory and the key difference between responder and nonresponders cells is the infectivity of the cells. Low or no CAR expression has already been reported in desmoids (37), and we confirm that CAR was absent from all the cellular samples tested, whether infectable with adenovirus or not. Taken together, these data suggest an alternative, CARindependent mechanism of infection. Such mechanisms have been suggested (38) and may involve heparan sulfate proteoglycans (39) or coagulation factors (40, 41) . Further studies will be required to address the mechanism of infection in these cells.
One of the particularity of desmoid tumors is their abundance in extracellular matrix that could prevent the diffusion of the virus in the tumor mass. In this context, pretreatment or coadministration of the oncolytic virus with enzymes capable of dissociating this matrix could enhance vector diffusion. A proof of principle has already been shown using hyaluronidase that was shown to improve adenoassociated virus-mediated gene transfer in the muscle (42), and this type of approach could be applied to the context of adenovirus gene therapy and desmoid tumors.
The fate of gene therapy vectors encoding NIS can be visualized after administration into a subject using positron emission tomography (22, 23) or single-photon emission computed tomography (18) . Both imaging methodologies are potentially applicable to humans and can provide unique information on the anatomic distribution of gene transfer. In addition, NIS can also be used as a therapeutic transgene through the administration of 131 I and the accumulation of radioactivity in tumor deposits transduced by the gene therapy vector (43, 44) . In this report, we show for the first time a direct effect of NIS expression on the viability cells. This effect is unique to primary desmoid cells as many different types of tumor cell lines can be transduced with the NIS gene without apparent toxicity and therapeutic doses of 131 I (45 -47) or high doses of nonradioactive iodide (48) are necessary to trigger cell death.
This report shows that gene therapy for desmoid tumor is feasible and the efficacy of the treatment is highly dependent on the infectivity of the cells. In the clinical setting, direct injection of the oncolytic adenovirus into desmoids under radiological guidance could be envisaged. This gene therapy approach would probably aim at debulking the tumor before attempting surgical resection, and in the case of a tumor susceptible to adenoviral infection, even a relatively modest effect could have an important clinical implication by making a previously unoperable intra-abdominal tumor amenable to surgery. Imaging of NIS gene transfer could also be done to provide additional information on the extent of gene transfer.
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